Polares Medical raises USD 50 million to advance its mitral valve replacement system

Lausanne-based Polares Medical has closed an oversubscribed USD 50 million Series C financing round to advance clinical studies of its MRace Posterior Leaflet Replacement system for mitral regurgitation across the US, Europe, and Australia.

Lausanne-based structural heart company Polares Medical has closed an oversubscribed USD 50 million Series C financing round. The round was led by DC Global Ventures and Lumination Partners, with participation from existing investors and a new strategic investor. Proceeds will fund the advancement of clinical studies in the United States, Europe, and Australia.

Polares Medical is developing the MRace Posterior Leaflet Replacement (PLR) system, a transcatheter device designed to treat mitral regurgitation, a heart valve condition in which blood leaks backward through the mitral valve with each contraction of the left ventricle. Mitral regurgitation affects a large patient population, particularly those with secondary MR, a condition currently addressed primarily through transcatheter edge-to-edge repair (TEER). While TEER has significantly advanced the treatment landscape, anatomical complexity limits its applicability in certain patients. MRace is designed to expand treatment options across a broader spectrum of mitral anatomies while preserving future therapeutic pathways.

The Series C builds on strong clinical momentum: MRace has now been implanted in more than 70 patients, with one-year data demonstrating sustained safety and efficacy. The Posterior Leaflet Replacement concept, which is positioned between conventional repair and total valve replacement, has been validated through this growing clinical experience.

Founded as a spinout of Swiss heart valve manufacturer Symetis, Polares Medical is headquartered in Lausanne with US operations in Palo Alto, California.